Current potentialities of chemotherapy for hormone-resistant cancer of the prostate
The purpose of the study was to reveal the most optimal treatment of hormone-resistant prostatic cancer (HRPC), by comparatively analyzing the efficiency and toxicity of 4 chemotherapy regimens: 1) mitoxantrone, 12 mg/m2, i.v. once 21 days; prednisolone, 10 mg/day (MP); 2) mitoxantrone, 12 mg/m2, i....
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2020-02-01
|
Series: | Onkourologiâ |
Online Access: | https://oncourology.abvpress.ru/oncur/article/view/1199 |